Literature DB >> 19135942

Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance.

Malgorzata Mikulska1, Valerio Del Bono, Anna Maria Raiola, Barbara Bruno, Francesca Gualandi, Domenico Occhini, Carmen di Grazia, Francesco Frassoni, Andrea Bacigalupo, Claudio Viscoli.   

Abstract

Blood stream infections (BSI) are a well-known cause of morbidity and mortality in hematopoietic stem cell transplant (HSCT) patients. The aim of this study was to analyze etiology and microbial resistance of BSI in patients undergoing allogeneic HSCT in a single center over a 4-year period (2004-2007). There were 168 episodes of BSI in 132 patients (median 10 days after HSCT) and 182 pathogens were isolated. Gram-positive bacteria (GPB) accounted for 57% of 182 isolates. Gram-negative rods (GNR) for 37% and fungi for 6%. All patients received routine fluoroquinolone prophylaxis. There was a significant decrease in GPB/GNR ratio over time, from 2.4 in 2004 to 1 in 2007 (P = .043). Among GPB, staphylococci decreased from 37 of 68 (64%) in 2004-2005 to 8 of 35 (23%) in 2006-2007 (P < .002). The Enterococcus faecalis/E. faecium ratio decreased from 4.5 in 2004 to 0.33 in 2007 (P = .006), whereas the total number of enterococcal strains per year did not change. The incidence of Escherichia coli among GNR increased from 3 of 15 (20%) in 2004 to 13 of 21 (62%) in 2007 (P = .003). Fluoroquinolone-resistance was common, both among GPB and GNR (81% and 74%, respectively). Mortality rate at 7 days after BSI was 11% (19 of 168), reaching 39% for Pseudomonas aeruginosa BSI (7 of 18). BSI remains a frequent and potentially life-threatening complication of allogeneic HSCT, the causative organism influencing 7- and 30-day mortality rate. BSI etiology may change rapidly, requiring implementation of new empirical-therapy schemes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19135942     DOI: 10.1016/j.bbmt.2008.10.024

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  63 in total

1.  Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.

Authors:  Margaret L Green; Wendy Leisenring; Daniel Stachel; Steven A Pergam; Brenda M Sandmaier; Anna Wald; Lawrence Corey; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-07       Impact factor: 5.742

2.  Colonization With Levofloxacin-resistant Extended-spectrum β-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients.

Authors:  Michael J Satlin; Kalyan D Chavda; Thomas M Baker; Liang Chen; Elena Shashkina; Rosemary Soave; Catherine B Small; Samantha E Jacobs; Tsiporah B Shore; Koen van Besien; Lars F Westblade; Audrey N Schuetz; Vance G Fowler; Stephen G Jenkins; Thomas J Walsh; Barry N Kreiswirth
Journal:  Clin Infect Dis       Date:  2018-11-13       Impact factor: 9.079

3.  Severe acute graft-versus-host disease increases the incidence of blood stream infection and mortality after allogeneic hematopoietic cell transplantation: Japanese transplant registry study.

Authors:  Yoshitaka Inoue; Keiji Okinaka; Shigeo Fuji; Yoshihiro Inamoto; Naoyuki Uchida; Takashi Toya; Kazuhiro Ikegame; Tetsuya Eto; Yukiyasu Ozawa; Koji Iwato; Yoshinobu Kanda; Yoshiko Atsuta; Masao Ogata; Takahiro Fukuda
Journal:  Bone Marrow Transplant       Date:  2021-04-19       Impact factor: 5.483

4.  Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients.

Authors:  D Averbuch; E Horwitz; J Strahilevitz; P Stepensky; N Goldschmidt; M E Gatt; M Y Shapira; I B Resnick; D Engelhard
Journal:  Infection       Date:  2013-05-08       Impact factor: 3.553

5.  Gut Colonization Preceding Mucosal Barrier Injury Bloodstream Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients.

Authors:  Matthew S Kelly; Doyle V Ward; Christopher J Severyn; Mehreen Arshad; Sarah M Heston; Kirsten Jenkins; Paul L Martin; Lauren McGill; Andre Stokhuyzen; Shakti K Bhattarai; Vanni Bucci; Patrick C Seed
Journal:  Biol Blood Marrow Transplant       Date:  2019-07-18       Impact factor: 5.742

6.  Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline.

Authors:  Bridgette L Therriault; John W Wilson; Jason N Barreto; Lynn L Estes
Journal:  Mayo Clin Proc       Date:  2010-08       Impact factor: 7.616

7.  European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Authors:  Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

8.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

9.  Incidence rate of fluoroquinolone-resistant gram-negative rod bacteremia among allogeneic hematopoietic cell transplantation patients during an era of levofloxacin prophylaxis.

Authors:  Arianna Miles-Jay; Susan Butler-Wu; Ali Rowhani-Rahbar; Steven A Pergam
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-11       Impact factor: 5.742

10.  Fluoroquinolone Prophylaxis Is Highly Effective for the Prevention of Central Line-Associated Bloodstream Infections in Autologous Stem Cell Transplant Patients.

Authors:  Matthew Ziegler; Daniel Landsburg; David Pegues; Warren Bilker; Cheryl Gilmar; Colleen Kucharczuk; Theresa Gorman; Kristen Bink; Amy Moore; Rebecca Fitzpatrick; Edward A Stadtmauer; Patricia Mangan; Kelly Kraus; Jennifer H Han
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-24       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.